Recent ADXN News
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 04/30/2026 08:01:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/30/2026 10:05:04 AM
- Addex Reports Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/30/2026 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 10:05:03 AM
- Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model • GlobeNewswire Inc. • 04/29/2026 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/23/2026 10:05:05 AM
- Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026 • GlobeNewswire Inc. • 04/23/2026 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/21/2026 10:05:05 AM
- Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model • GlobeNewswire Inc. • 04/21/2026 05:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 08:03:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 08:02:26 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 08:01:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 08:01:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 03:06:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/03/2026 11:05:03 AM
- Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment • GlobeNewswire Inc. • 02/03/2026 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/07/2026 11:05:05 AM
- Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia • GlobeNewswire Inc. • 01/07/2026 06:00:00 AM
- Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. • GlobeNewswire Inc. • 12/11/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/10/2025 09:03:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/10/2025 09:01:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/04/2025 11:00:31 AM
- Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 12/04/2025 06:00:00 AM
